Lifecore Biomedical Inc. (LFCR) - Total Assets
Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) holds total assets worth $229.50 Million USD as of May 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lifecore Biomedical Inc. - Total Assets Trend (1996–2026)
This chart illustrates how Lifecore Biomedical Inc.'s total assets have evolved over time, based on quarterly financial data. Also see LFCR market cap overview for the company's overall valuation and market capitalisation.
Lifecore Biomedical Inc. - Asset Composition Analysis
Current Asset Composition (May 2026)
Lifecore Biomedical Inc.'s total assets of $229.50 Million consist of 35.4% current assets and 64.6% non-current assets. Review LFCR total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.5% |
| Accounts Receivable | $33.82 Million | 14.6% |
| Inventory | $29.09 Million | 12.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.20 Million | 1.8% |
| Goodwill | $13.88 Million | 6.0% |
Asset Composition Trend (1996–2026)
This chart illustrates how Lifecore Biomedical Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Lifecore Biomedical Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lifecore Biomedical Inc.'s current assets represent 35.4% of total assets in 2026, a decrease from 97.1% in 1996.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2026, down from 37.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 14.6% of total assets.
Lifecore Biomedical Inc. Competitors by Total Assets
Key competitors of Lifecore Biomedical Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Lifecore Biomedical Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.87 | 2.84 | 1.46 |
| Quick Ratio | 2.69 | 1.77 | 0.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $62.05 Million | $55.50 Million | $46.43 Million |
Lifecore Biomedical Inc. - Advanced Valuation Insights
This section examines the relationship between Lifecore Biomedical Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 197.99 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | $232.18 Million |
| Market Capitalization | $156.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lifecore Biomedical Inc.'s assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Lifecore Biomedical Inc.'s assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Lifecore Biomedical Inc. (1996–2026)
The table below shows the annual total assets of Lifecore Biomedical Inc. from 1996 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-05-31 | $232.18 Million | -2.99% |
| 2025-05-31 | $239.34 Million | -5.76% |
| 2024-05-31 | $253.96 Million | -7.55% |
| 2023-05-31 | $274.70 Million | -6.93% |
| 2022-05-31 | $295.16 Million | -41.31% |
| 2021-05-31 | $502.92 Million | -7.09% |
| 2020-05-31 | $541.31 Million | +4.28% |
| 2019-05-31 | $519.09 Million | +28.26% |
| 2018-05-31 | $404.70 Million | +13.04% |
| 2017-05-31 | $358.01 Million | +4.23% |
| 2016-05-31 | $343.47 Million | -0.86% |
| 2015-05-31 | $346.46 Million | +10.47% |
| 2014-05-31 | $313.62 Million | +7.80% |
| 2013-05-31 | $290.94 Million | +4.77% |
| 2012-05-31 | $277.69 Million | +34.60% |
| 2011-05-31 | $206.31 Million | +3.05% |
| 2010-05-31 | $200.20 Million | +30.96% |
| 2009-05-31 | $152.87 Million | +1.51% |
| 2008-05-31 | $150.59 Million | +6.52% |
| 2007-05-31 | $141.37 Million | +18.77% |
| 2006-05-31 | $119.03 Million | +18.94% |
| 2005-05-31 | $100.08 Million | +7.60% |
| 2004-05-31 | $93.01 Million | -4.29% |
| 2003-05-31 | $97.17 Million | -9.86% |
| 2002-05-31 | $107.80 Million | -10.26% |
| 2001-05-31 | $120.12 Million | -2.92% |
| 2000-05-31 | $123.73 Million | +204.01% |
| 1999-05-31 | $40.70 Million | -4.01% |
| 1998-05-31 | $42.40 Million | -15.54% |
| 1997-05-31 | $50.20 Million | +30.73% |
| 1996-05-31 | $38.40 Million | -- |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more